Market Overview

UPDATE: Canaccord Genuity Reiterates Buy Rating, Raises PT on Mylan

Share:
Related MYL
Deutsche Tweaking Its Mylan View Following CEO's Congressional Testimony
USA Today On EpiPen Saga: Calling It 'Controversial' Is Far From Haphazard
Biotech Forum Daily Digest: Can Biotech Broach Resistance Levels? Worst Now Over For Mylan? Spotlight Feature On Bellicum Pharmaceuticals (Seeking Alpha)

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Mylan (NASDAQ: MYL), and slightly raised its price target from $30.00 to $31.00.

Canaccord Genuity noted, “We held meetings in various cities pre and post the long weekend. MYL drove the most discussion, and we've taken a closer look the five most asked questions and our thoughts on each. We still like the combination of earnings upside (on reasonable expectations), highly defendable valuation and near-term catalysts supporting upside potential. After a revisit to our model and catch-up with MYL , we're raising our target to $31 on higher EPIPEN-driven EPS and reaffirming our BUY rating and positive stance on the sector. We're currently at the World Generic Medicines Congress Americas meeting where we expect to pick up additional sector data points.”

Mylan closed on Tuesday at $27.20.

Latest Ratings for MYL

DateFirmActionFromTo
Sep 2016Deutsche BankMaintainsBuy
Aug 2016Leerink SwannMaintainsOutperform
May 2016Leerink SwannMaintainsOutperform

View More Analyst Ratings for MYL
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (MYL)

View Comments and Join the Discussion!